HUE071725T2 - Vegyületek figyelemhiányos hiperaktivitási zavar kezelésében való alkalmazásra - Google Patents
Vegyületek figyelemhiányos hiperaktivitási zavar kezelésében való alkalmazásraInfo
- Publication number
- HUE071725T2 HUE071725T2 HUE22708379A HUE22708379A HUE071725T2 HU E071725 T2 HUE071725 T2 HU E071725T2 HU E22708379 A HUE22708379 A HU E22708379A HU E22708379 A HUE22708379 A HU E22708379A HU E071725 T2 HUE071725 T2 HU E071725T2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- treatment
- attention deficit
- hyperactivity disorder
- deficit hyperactivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2101292.7A GB202101292D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101291.9A GB202101291D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101296.8A GB202101296D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE071725T2 true HUE071725T2 (hu) | 2025-09-28 |
Family
ID=80682355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE22708379A HUE071725T2 (hu) | 2021-01-29 | 2022-01-28 | Vegyületek figyelemhiányos hiperaktivitási zavar kezelésében való alkalmazásra |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240130995A1 (https=) |
| EP (1) | EP4284356B1 (https=) |
| JP (1) | JP2024508372A (https=) |
| AU (1) | AU2022215118A1 (https=) |
| CA (1) | CA3206935A1 (https=) |
| ES (1) | ES3038949T3 (https=) |
| HR (1) | HRP20250747T1 (https=) |
| HU (1) | HUE071725T2 (https=) |
| PL (1) | PL4284356T3 (https=) |
| RS (1) | RS66934B1 (https=) |
| SM (1) | SMT202500238T1 (https=) |
| WO (1) | WO2022162199A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093748A1 (en) * | 2023-11-03 | 2025-05-08 | 3Z Pharmaceuticals | Use of a calcium channel blocker in the treatment of adhd |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030672A1 (en) * | 1997-11-19 | 2000-08-30 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| CA2546395A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| EP1609783A1 (en) * | 2004-06-17 | 2005-12-28 | Neuropharma S.A.U. | Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment |
| US20080226715A1 (en) * | 2007-03-16 | 2008-09-18 | Albert Cha | Therapeutic compositions and methods |
| WO2011100659A2 (en) * | 2010-02-12 | 2011-08-18 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| PL2895507T3 (pl) * | 2012-09-11 | 2019-04-30 | Inst Catalana De Recerca I Estudis Avancats | Sposób diagnostyczny do wykrywania choroby autoimmunologicznej oraz przedmioty z nim związane |
| WO2014133329A1 (ko) * | 2013-02-27 | 2014-09-04 | 에스케이케미칼 주식회사 | 관절염 치료용 복합 제제 |
| KR20140135676A (ko) * | 2014-10-02 | 2014-11-26 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 ｔ―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| JP2021500416A (ja) * | 2017-10-27 | 2021-01-07 | エステベ ファーマスーティカルズ，ソシエダッド アノニマ | 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体 |
| WO2020120606A1 (en) * | 2018-12-12 | 2020-06-18 | Esteve Pharmaceuticals, S.A. | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions |
-
2022
- 2022-01-28 SM SM20250238T patent/SMT202500238T1/it unknown
- 2022-01-28 RS RS20250624A patent/RS66934B1/sr unknown
- 2022-01-28 JP JP2023546027A patent/JP2024508372A/ja active Pending
- 2022-01-28 HU HUE22708379A patent/HUE071725T2/hu unknown
- 2022-01-28 AU AU2022215118A patent/AU2022215118A1/en active Pending
- 2022-01-28 CA CA3206935A patent/CA3206935A1/en active Pending
- 2022-01-28 WO PCT/EP2022/052142 patent/WO2022162199A2/en not_active Ceased
- 2022-01-28 US US18/274,945 patent/US20240130995A1/en active Pending
- 2022-01-28 PL PL22708379.7T patent/PL4284356T3/pl unknown
- 2022-01-28 ES ES22708379T patent/ES3038949T3/es active Active
- 2022-01-28 EP EP22708379.7A patent/EP4284356B1/en active Active
- 2022-01-28 HR HRP20250747TT patent/HRP20250747T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3206935A1 (en) | 2022-08-04 |
| SMT202500238T1 (it) | 2025-07-22 |
| PL4284356T3 (pl) | 2025-07-28 |
| JP2024508372A (ja) | 2024-02-27 |
| WO2022162199A2 (en) | 2022-08-04 |
| EP4284356A2 (en) | 2023-12-06 |
| HRP20250747T1 (hr) | 2025-08-15 |
| AU2022215118A1 (en) | 2023-08-17 |
| AU2022215118A9 (en) | 2024-05-16 |
| EP4284356B1 (en) | 2025-04-02 |
| EP4284356C0 (en) | 2025-04-02 |
| RS66934B1 (sr) | 2025-07-31 |
| US20240130995A1 (en) | 2024-04-25 |
| WO2022162199A3 (en) | 2022-09-15 |
| ES3038949T3 (en) | 2025-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290415A (en) | Compounds with deuterium for use in cancer treatment | |
| IL292530B2 (en) | Pyruvate kinase activators for use in the treatment of blood disorders | |
| SI3435996T1 (sl) | Elafibranor za uporabo pri zdravljenju primarnega žolčnega holangitisa | |
| IL266764A (en) | Gaboxadol for use in methods of treating attention deficit/hyperactivity disorder | |
| PT3426232T (pt) | Comprimido multicamadas de mazindol ir/sr e a sua utilização para o tratamento do distúrbio de hiperatividade/défice de atenção (adhd) | |
| SMT202500434T1 (it) | Sotorasib per l'uso nel trattamento del cancro | |
| HUE071725T2 (hu) | Vegyületek figyelemhiányos hiperaktivitási zavar kezelésében való alkalmazásra | |
| EP2806736A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT | |
| PL2844277T3 (pl) | Oksydaza diaminowa do stosowania w leczeniu lub zapobieganiu zespołowi nadpobudliwości z deficytem uwagi (ADHD) | |
| IL278763A (en) | Methods for treating attention deficit hyperactivity disorder | |
| PL4146225T3 (pl) | Związki metylotioniniowe do zastosowania w leczeniu hipoksemii | |
| PL3941465T3 (pl) | Sposoby leczenia zespołu nadpobudliwości psychoruchowej z deficytem uwagi z zastosowaniem inhibitorów kdm1a, takich jak związek wafidemstat | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. | |
| HUE066554T2 (hu) | Keverõ egység szennyvízkezelõ berendezésekben kezelt folyadékok keveréséhez | |
| IL284953A (en) | Methylphenidate compositions for treatment of attention deficit hyperactivity disorder | |
| MX2016014768A (es) | Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. | |
| IL232897B (en) | Pacetopran for the treatment of attention, concentration and hyperactivity disorder | |
| BRPI1014545A2 (pt) | composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade | |
| EP4389126A4 (en) | Pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder | |
| HK40065152A (en) | Methylphenidate compositions for treatment of attention deficit hyperactivity disorder | |
| PT3082798T (pt) | Derivados de benzodioxol para uso no tratamento do défice de atenção e/ou hiperatividade | |
| GB201415260D0 (en) | Aerator For Use in sewage treatment | |
| GB201415259D0 (en) | Aerator for use in sewage treatment |